Pulmonary arterial hypertension: Sex matters
British Journal of Pharmacology · 2024-04 · 181 (7) · 938-966
DOI: 10.1111/bph.16277 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-01-16. Written by Joshua P Dignam and 3 co-authors. Institution: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK. Major MEDLINE topics: Pulmonary Arterial Hypertension, Hypertension, Pulmonary, Ventricular Dysfunction, Right. Cited 46 times so far (Crossref); 289 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, British Heart Foundation.
Abstract (original language)
Pulmonary arterial hypertension (PAH) is a complex disease of multifactorial origin. While registries have demonstrated that women are more susceptible to the disease, females with PAH have superior right ventricle (RV) function and a better prognosis than their male counterparts, a phenomenon referred to as the ‘estrogen paradox’. Numerous pre‐clinical studies have investigated the involvement of sex hormones in PAH pathobiology, often with conflicting results. However, recent advances suggest that abnormal estrogen synthesis, metabolism and signalling underpin the sexual dimorphism of this disease. Other sex hormones, such as progesterone, testosterone and dehydroepiandrosterone may also play a role. Several non‐hormonal factor including sex chromosomes and epigenetics have also been implicated. Though the underlying pathophysiological mechanisms are complex, several compounds that modulate sex hormones levels and signalling are under investigation in PAH patients. Further elucidation of the estrogen paradox will set the stage for the identification of additional therapeutic targets for this disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK.
- Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, UK.
Funding
- Medical Research Council
- British Heart Foundation
Cite
APA
Dignam, J. P., Sharma, S., Stasinopoulos, I., & MacLean, M. R. (2024). Pulmonary arterial hypertension: Sex matters. British Journal of Pharmacology, 181(7), 938-966. https://doi.org/10.1111/bph.16277
Vancouver
Dignam JP, Sharma S, Stasinopoulos I, MacLean MR. Pulmonary arterial hypertension: Sex matters. British Journal of Pharmacology. 2024;181(7):938-966. doi:10.1111/bph.16277
BibTeX
@article{Dignam2024,
author = {Dignam, Joshua P and Sharma, Smriti and Stasinopoulos, Ioannis and MacLean, Margaret R},
title = {Pulmonary arterial hypertension: Sex matters},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {7},
pages = {938--966},
doi = {10.1111/bph.16277}
}
EUVIMED